Group 1 - The article highlights the increasing pain felt by various industries due to China's rare earth export control measures, prompting foreign manufacturers to accelerate the establishment of their own rare earth supply chains [1][3] - U.S. rare earth manufacturers express confidence in their ability to make significant progress within a year, indicating a strong demand for rare earth resources that have traditionally been supplied by China [1][3] - China controls approximately 70% of global rare earth mining, 85% of refining capacity, and about 90% of rare earth metal alloys and magnet production, showcasing its monopolistic position in the global rare earth processing sector [3] Group 2 - From 2020 to 2023, 70% of U.S. rare earth compounds and metals were imported from China, highlighting the U.S. reliance on Chinese supplies and the determination to reduce this dependency [3] - Some U.S. scholars and media express skepticism about the future of the U.S. rare earth industry, suggesting that the era of U.S. dominance may be coming to an end [3][5] - The U.S. pharmaceutical industry is heavily reliant on China, with over 60% of daily medications and raw materials sourced from China, indicating a significant vulnerability in the U.S. healthcare supply chain [5][7] Group 3 - The article suggests that if the U.S. continues its policies of manufacturing repatriation and tariff threats, it may lead to a situation where American pharmaceutical companies could abandon the U.S. market, resulting in a potential shortage of medications [7] - The actions taken by the U.S. under the Trump administration are portrayed as exposing weaknesses in American hegemony, while China is advised to focus on its own development and respond appropriately to U.S. actions [7]

一群小企业在一场可能对共和党经济议程产生重大影响的法庭听证会上敦促美国贸易法庭阻止总统特朗 普4月2日挑起的全球对等关税。5月13日，这些企业和特朗普政府的律师在位于曼哈顿的美国国际贸易 法院发表了辩论。 该法院由三名法官组成的陪审团正在权衡是否发布针对这些关税的全国性禁令，以及如果发布，禁令将 持续多长时间。这些企业辩称，特朗普援引了虚假的国家紧急状态来为征税辩护，而司法部则表示，总 统的决定不应接受法院审查。陪审团尚未发布裁决，裁决将在稍后公布。 ...